MX2017016024A - Composiciones de nicotinamida ribósido y pteroestilbeno y métodos para el tratamiento de trastornos de la piel. - Google Patents

Composiciones de nicotinamida ribósido y pteroestilbeno y métodos para el tratamiento de trastornos de la piel.

Info

Publication number
MX2017016024A
MX2017016024A MX2017016024A MX2017016024A MX2017016024A MX 2017016024 A MX2017016024 A MX 2017016024A MX 2017016024 A MX2017016024 A MX 2017016024A MX 2017016024 A MX2017016024 A MX 2017016024A MX 2017016024 A MX2017016024 A MX 2017016024A
Authority
MX
Mexico
Prior art keywords
skin disorders
methods
nicotinamide riboside
compositions
treatment
Prior art date
Application number
MX2017016024A
Other languages
English (en)
Inventor
Antonio Alminana Daniel
Alexander Marcotulli Eric
Michael Bowen Paul
Pershing Guarente Leonard
Original Assignee
Elysium Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elysium Health Inc filed Critical Elysium Health Inc
Publication of MX2017016024A publication Critical patent/MX2017016024A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Se describen composiciones que contienen una combinación de nicotinamida ribósido y pteroestilbeno para tratar trastornos de la piel, y métodos para tratar trastornos de la piel empleando estas composiciones y sus equivalentes. Los trastornos de la piel que se tratan empleando estas composiciones o métodos incluyen trastornos de la piel relacionados con la exposición al sol, trastornos inflamatorios de la piel, trastornos de la piel relacionados con enfermedades autoinmunológicas y trastornos de la piel relacionados con el cáncer. En una realización, las composiciones que contienen una combinación de nicotinamida ribósido y pteroestilbeno se preparan como formulaciones orales.
MX2017016024A 2015-06-10 2016-02-25 Composiciones de nicotinamida ribósido y pteroestilbeno y métodos para el tratamiento de trastornos de la piel. MX2017016024A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562173733P 2015-06-10 2015-06-10
PCT/US2016/019653 WO2016200447A1 (en) 2015-06-10 2016-02-25 Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders

Publications (1)

Publication Number Publication Date
MX2017016024A true MX2017016024A (es) 2018-08-15

Family

ID=57503873

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017016024A MX2017016024A (es) 2015-06-10 2016-02-25 Composiciones de nicotinamida ribósido y pteroestilbeno y métodos para el tratamiento de trastornos de la piel.
MX2021012600A MX2021012600A (es) 2015-06-10 2017-12-08 Composiciones de nicotinamida ribosido y pteroestilbeno y metodos para el tratamiento de trastornos de la piel.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021012600A MX2021012600A (es) 2015-06-10 2017-12-08 Composiciones de nicotinamida ribosido y pteroestilbeno y metodos para el tratamiento de trastornos de la piel.

Country Status (13)

Country Link
US (2) US11426398B2 (es)
EP (1) EP3307754B1 (es)
JP (1) JP2018517774A (es)
KR (1) KR20180021784A (es)
CN (1) CN107849083A (es)
AU (2) AU2016274126A1 (es)
CA (1) CA2989115C (es)
ES (1) ES2932801T3 (es)
MX (2) MX2017016024A (es)
RU (1) RU2017145692A (es)
TW (1) TWI725033B (es)
WO (1) WO2016200447A1 (es)
ZA (1) ZA201800056B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017394032B8 (en) 2017-01-21 2020-10-22 Guangzhou Hanfang Pharmaceutical Co., Ltd. Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
CN110769834A (zh) 2017-03-17 2020-02-07 益力舒健康公司 用于治疗或预防肝损伤的烟酰胺核苷
AU2018260616B2 (en) * 2017-04-24 2022-09-15 Elysium Health, Inc. Treating and preventing kidney damage
US11730751B2 (en) 2017-05-17 2023-08-22 Universitat De València-Estudi General Treating and preventing motor neuron diseases using nicotinamide riboside
EP3624808A4 (en) * 2017-05-18 2021-03-03 Elysium Health, Inc. PROCEDURES AND COMPOSITIONS FOR IMPROVED SLEEP
WO2019023471A1 (en) * 2017-07-28 2019-01-31 Centers For Age Control, Inc. COMPOSITIONS AND METHODS FOR PREVENTING AND INVERTING THE ASPECTS OF AGING
CN109589309A (zh) * 2017-09-30 2019-04-09 浙江嘉华化工有限公司 烟酰胺核糖微囊的制备方法
CN111601814A (zh) * 2017-10-19 2020-08-28 益力舒健康公司 Tdp-43相关疾病的预防和治疗
US20210186996A1 (en) * 2017-12-01 2021-06-24 Elysium Health, Inc. Methods and compositions for treating multiple sclerosis
WO2019108875A1 (en) * 2017-12-01 2019-06-06 Elysium Health, Inc. Methods and compositions for treating glaucoma
GB201811312D0 (en) * 2018-07-10 2018-08-29 Nuchido Ltd Compositions
US11802103B2 (en) 2018-09-25 2023-10-31 Ponce De Leon Health Designated Activity Company Process of making calcium alpha-ketoglutarate
CN111569084B (zh) * 2019-02-19 2021-07-13 中国科学院上海药物研究所 基于柳胺酚和紫檀芪的成环偶联分子dcz0801类化合物、其制备方法及用途
WO2020190703A1 (en) * 2019-03-21 2020-09-24 Elysium Health, Inc. Methods for wound treatment
CN113712193A (zh) * 2020-05-25 2021-11-30 南京帝昌医药科技有限公司 修复皮肤系统的组合物制备方法及其用途
CN113768946A (zh) * 2020-05-25 2021-12-10 南京帝昌医药科技有限公司 一种治疗糖尿病皮肤并发症的软膏及其制备方法
WO2022026612A1 (en) * 2020-07-30 2022-02-03 Hernandez Vazquez Moises Nutritional supplements for repairing muscle and defending against deterioration from human aging
WO2023012182A1 (en) * 2021-08-02 2023-02-09 Nuvamid Sa Nicotinamide mononucleotide derivatives for use in the treatment of sapho syndrome
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO2007061798A2 (en) * 2005-11-18 2007-05-31 Cornell Research Foundation, Inc. Nicotinoyl riboside compositions and methods of use
EP2322159A1 (en) 2009-10-30 2011-05-18 Green Molecular, S.L. Use of pterostilbene (pter) as medicament for prevention and/or treatment of skin diseases, damages or injures or as cosmetic
WO2012129499A1 (en) 2011-03-23 2012-09-27 The Regents Of The University Of California Treatment of inflammatory and infectious skin disorders
US8841350B2 (en) 2011-05-11 2014-09-23 ChromaDex Inc. Method for inducing UDP-glucuronosyltransferase activity using pterostilbene
US20130296440A1 (en) 2012-05-01 2013-11-07 ChromaDex Inc. Pterostilbene and curcumin combination for treatment of oxidative stress and inflammation
KR20220098049A (ko) * 2013-10-30 2022-07-08 크로마덱스 아이엔씨. 피부 질환 치료에서의 국소적 사용을 위한 니코틴아미드 리보사이드 조성물
RU2016149767A (ru) * 2014-06-06 2018-07-16 Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед Аналоги никотинамидрибозида и фармацевтические композиции и их применение
CN111643512A (zh) * 2015-03-16 2020-09-11 可劳迈戴斯有限公司 烟酸核苷或烟酰胺核苷组合物、其还原衍生物及其用途
US20180071273A1 (en) * 2015-03-17 2018-03-15 Speccialty Nutrition Group, Inc. Nutritional compositions to enhance mitochondrial energy production

Also Published As

Publication number Publication date
ES2932801T3 (es) 2023-01-26
US11426398B2 (en) 2022-08-30
AU2020286208A1 (en) 2021-01-07
EP3307754A4 (en) 2019-03-27
TWI725033B (zh) 2021-04-21
KR20180021784A (ko) 2018-03-05
AU2016274126A1 (en) 2018-01-18
TW201713322A (zh) 2017-04-16
CA2989115C (en) 2024-01-02
WO2016200447A1 (en) 2016-12-15
RU2017145692A3 (es) 2019-07-31
US20220362233A1 (en) 2022-11-17
CN107849083A (zh) 2018-03-27
JP2018517774A (ja) 2018-07-05
MX2021012600A (es) 2021-11-12
RU2017145692A (ru) 2019-07-10
ZA201800056B (en) 2023-10-25
US20180353497A1 (en) 2018-12-13
EP3307754B1 (en) 2022-09-14
EP3307754A1 (en) 2018-04-18
AU2020286208B2 (en) 2022-11-10
CA2989115A1 (en) 2016-12-15

Similar Documents

Publication Publication Date Title
ZA201800056B (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
PH12020551923A1 (en) Methods and compositions for treating cancer
MX2018011114A (es) Métodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatías.
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
MX2018006745A (es) Metodos de tratamiento de neoplasias malignas.
MY187540A (en) Compounds active towards bromodomains
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
NZ631701A (en) Apoptosis-including agents for the treatment of cancer and immune and autoimmune diseases
GB2541571A (en) Pharmaceutical compositions
IL276808A (en) Preparations and methods for the treatment of cancer
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
WO2017079570A3 (en) Splise-switching oligonucleotides and methods of use
MX2020001774A (es) Composiciones y métodos para tratar enfermedad colestásica.
BR112019003579A2 (pt) Composições de ribosídeo de nicotinamida e pterostilbeno e métodos para o tratamento dedistúrbios neurodegenerativos
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
MX2019009753A (es) Composicion y metodos para prevenir lesion por radiacion y promover la regeneracion de tejidos.
MY195081A (en) Pladienolide Pyridine Compounds and Methods of use
MX2017002489A (es) Agentes terapeuticos humanos.
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
MX2017013047A (es) Tratamiento de dolor.
EP3413906A4 (en) COMBINATION COMPOSITIONS FOR CANCER TREATMENT, METHOD AND USES
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
TW201713323A (en) Therapeutic compositions and methods of use thereof